Medtronic (NYSE:MDT) said today its Micra transcatheter pacing system and MiniMed 640G-based Hybrid Closed Loop system have both won Popular Science‘s Best of What’s New 2015 award in the health category.
The Micra transcatheter pacing system, which at 1/10th the size of a conventional pacemaker is roughly the size of a large vitamin, is designed to be implanted via catheter in the right ventricle to deliver single-chamber pacing, Medtronic said. The Micra device has an estimated 12-year battery life and is approved as safe for full-body MRI scans, the company said.
Medtronic’s experimental Hybrid Closed Loop system, currently in a pivotal clinical trial, is built upon the company’s MiniMed 640G and designed to automatically control glucose levels 24/7 with only carbohydrate data at mealtime and occasional sensor calibrations.
The 2 products from the Fridley, Minn.-based medical giant were among 100 selected by Popular Science to represent “a significant leap forward in their respective categories,” Medtronic said.
“The Best of What’s New awards honor the innovations that surprise and amaze us-those that challenge our view of what’s possible in the future. The award is Popular Science’s top prize, and the 100 winners-chosen from among thousands of nominees-are each a revolution in their respective fields,” Popular Science editor-in-chief Cliff Ransom said in a press release.
Both products are featured in Popular Science’s December issue.
Last week, Medtronic’s Micra pacer system met its primary safety and effectiveness endpoints with “wide margins,” the company said today. Results from the trial were presented at the American Heart Association’s scientific sessions meeting this week and published in the New England Journal of Medicine, Medtronic said.
Medtronic said that 99.2% of patients in the trial were successfully implanted with the device. A total 96% of 725 patients experienced no major complications, which Medtronic said is 51% less than is seen in patients with conventional pacing systems.
In June, Medtronic said it enrolled the 1st patient in a pivotal study of its Hybrid Closed Loop system. Medtronic claimed it is the 1st pivotal trial of a closed loop system conducted in the U.S. The single-arm, multi-center clinical study is slated to enroll 150 Type I diabetics, the company added.